ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2015
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.
13 registry-linked trialsAbstract read
In one paragraph
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 13 registered trials, which are not on this map. Cited by 1,461 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1,461citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma
An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children and Young Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
Natural History of Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
2177GCCC: Identifying Novel Treatment Targets and Biomarkers for Ocular Surface Disease in Patients With Ocular Graft vs Host Disease (oGVHD) a Biobank Study
NCT06348602 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation
Evaluation of Safety and Efficacy for the Prevention of Ocular Graft-versus-host Disease With Ophthalmic Tacrolimus vs. Ophthalmic Cyclosporine in Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplant Recipients
A Nation-wide, Multi-center, Prospective, Randomized, Parallel-group, Open-label, Investigator Initiated Pilot Study to Evaluate Efficacy and Safety of Systemic Corticosteroid Plus Ruxolitinib as First-line Therapy in Patients With New-onset Moderate to Severe Chronic Graft-versus-host Disease
SHARP - Safely Delivered Targeted High-dose Irradiation Followed by Adoptive Immunotherapy with Regulatory and Conventional T Cells to Increase Potency of Hematopoietic Stem Cell Transplantation in High-risk Acute Leukemia
NCT07078721 phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation
Efficacy and Safety Study of Umbilical Cord Blood Transplantation (UCBT) With Total Marrow Irradiation (TMI)-Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia (AA).
NCT07502118 phase2 / phase3recruitingnot on this mapstarted 2025, after this paper: background citation
An Open-Label, Multicenter Phase 2-3 Clinical Study of Anti-CD19 Chimeric Antigen Receptor T Cells (Talikabtagene Autoleucel) in Patients With Relapsed/Refractory B-Cell Malignancies (NexCAR19)
NCT07576699 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
Who cites it
1,461 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Evolving Paradigms in Chronic Graft-Versus-Host Disease: From Global Immunosuppression to Precision Targeted and Cell-Based Therapies.Stem cell reviews and reports · 2026Pooled it
- Toward Better Response Assessment of Cutaneous Chronic Graft-Versus-Host Disease: A Report from the National Institutes of Health Consensus Project Task Force.Transplantation and cellular therapy · 2026Guideline
- Chronic graft versus host disease in upper limb: Calling upper limb rehabilitation specialists for improving outcomes in patients.Clinical hematology international · 2026Pooled it
- Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.American journal of hematology · 2026Trial
- Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial.The Lancet. Haematology · 2026Trial
- Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.Signal transduction and targeted therapy · 2026Trial
- Trial
- Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease.Blood advances · 2026Trial
- CRISPR-Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial.Nature medicine · 2026Trial
- Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial.Nature communications · 2026Trial
- Trial
- The BIOPREVENT machine-learning algorithm predicts chronic graft-versus-host disease and mortality risk using posttransplant biomarkers.The Journal of clinical investigation · 2026Trial
- Efficacy and safety of the single-dose pegylated G-CSF vs. daily G-CSF for peripheral blood stem cells mobilization in donors: a multicenter, randomized controlled trial.Frontiers in immunology · 2026Trial
- Pre-Hematopoietic Cell Transplantation Ruxolitinib in Transplantation-Eligible Patients with Myelofibrosis: Long-Term Outcomes of a Phase II Prospective Study.Transplantation and cellular therapy · 2026Trial
- Randomized trial of anti-thymocyte globulin plus lowdose post-transplant cyclophosphamide to prevent graft-Haematologica · 2025Trial
- Cord blood transfusion added matched unrelated donor transplantation as a preferable choice for aplastic anaemia: a comparative study from a single centre.Annals of medicine · 2026Article
- Gynaecological complications and vulvovaginal graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a retrospective study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Observational
- Chronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development.Blood advances · 2026Observational
- Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP.Bone marrow transplantation · 2026Article
- PTCy-Based versus ATG-Based GVHD Prophylaxis in Mismatched Unrelated Donor HCT: A Secondary Analysis of CIBMTR Data.Transplantation and cellular therapy · 2026Article
1,401 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Madan H JagasiaDepartment of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Hildegard T GreinixDepartment of Internal Medicine, Medical University of Vienna, Vienna, Austria.
Mukta AroraDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota.
Kirsten M WilliamsCenter for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Department of Blood and Marrow Transplantation, Children's National Health System, Washington, District of Columbia.
Daniel WolffDepartment of Internal Medicine, University of Regensburg, Regensburg, Germany.
Edward W CowenCenter for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Jeanne PalmerDepartment of Hematology Oncology/Blood and Marrow Transplant, Mayo Clinic Arizona, Phoenix, Arizona.
Daniel WeisdorfDepartment of Medicine, University of Minnesota, Minneapolis, Minnesota.
Nathaniel S TreisterDepartment of Surgery, Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Boston, Massachusetts.
Guang-Shing ChengClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Holly KerrHematology Department, BC Cancer Agency, Vancouver, British Columbia, Canada.
Pamela StrattonPediatric and Reproductive Endocrinology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
Rafael F DuarteDepartment of Hematology, Institut Catala d'Oncologia, Barcelona, Spain.
George B McDonaldClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Afonso VigoritoHematology and Hemotherapy Center, Hemocentro Unicamp, Campinas, Sao Paulo, Brazil.
Sally AraiDepartment of Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, California.
Manuel B DatilesThe Eye Clinic, National Eye Institute, National Institutes of Health, Bethesda, Maryland.
David JacobsohnDepartment of Blood and Marrow Transplantation, Children's National Health System, Washington, District of Columbia.
Theo HellerLiver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Disease, National Institutes of Health, Bethesda, Maryland.
Carrie L KitkoBlood and Marrow Transplant Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
Sandra A MitchellDepartment of Applied Research Cancer Control and Population Sciences, National Institutes of Health, Bethesda, Maryland.
Paul J MartinClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Howard ShulmanClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Roy S WuCancer Therapy Evaluation Program, National Institutes of Health, Bethesda, Maryland.
Corey S CutlerDivision of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Georgia B VogelsangOncology Department, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Stephanie J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Steven Z PavleticCenter for Cancer Research National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: mflowers@fredhutch.org.
Funding
VIRUS-MEDIATED MYELOSUPPRESSIONP01CA018029 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Geoffrey Roger HILL · 1985 to 2026
$128.4MImproving Outcomes Assessment in Chronic GVHDR01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2011 to 2025
$8.3MChronic graft-versus-host diseaseZIABC011549 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI COWEN, EDWARD · 2014 to 2021
$5.2MImproving Outcomes Assessment in Chronic GVHDU01CA118953 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI LEE, STEPHANIE J · 2007 to 2010
$3.1MSafety and Immunogenicity of Gardasil post stem cell transplantationZIAHD008900 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI STRATTON, PAMELA · 2010 to 2016
$1.2MA Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) PatientsZIAEY000540 · NEI · NATIONAL EYE INSTITUTE · PI DATILES, MANUEL B · 2014 to 2016
$795kNCI NIH HHS CA118953NCI NIH HHS CA18029NCI NIH HHS P01 CA018029NCI NIH HHS R01 CA118953NCI NIH HHS U01 CA118953
Abstract
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosing and scoring the severity of chronic graft-versus-host disease (GVHD). The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence. Revisions have been made to address areas of controversy or confusion, such as the overlap chronic GVHD subcategory and the distinction between active disease and past tissue damage. Diagnostic criteria for involvement of mouth, eyes, genitalia, and lungs have been revised. Categories of chronic GVHD should be defined in ways that indicate prognosis, guide treatment, and define eligibility for clinical trials. Revisions have been made to focus attention on the causes of organ-specific abnormalities. Attribution of organ-specific abnormalities to chronic GVHD has been addressed. This paradigm shift provides greater specificity and more accurately measures the global burden of disease attributed to GVHD, and it will facilitate biomarker association studies.
Indexed as
BiomarkersChronic DiseaseClinical Trials as TopicConsensusConsensus Development Conferences, NIH as TopicFemaleGraft vs Host DiseaseHumansMaleOrgan SpecificityPractice Guidelines as TopicUnited StatesBiomarkersChronic graft-versus-host diseaseDiagnosisNational Institutes of HealthStaging
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT00896493ClinicalTrials.gov
NCT02123966ClinicalTrials.gov
NCT02206035ClinicalTrials.gov
NCT02626715ClinicalTrials.gov
NCT03267186ClinicalTrials.gov
NCT03602599ClinicalTrials.gov
and 7 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.